234 related articles for article (PubMed ID: 20012301)
1. Functional analysis of LOXL2 in pancreatic carcinoma.
Rückert F; Joensson P; Saeger HD; Grützmann R; Pilarsky C
Int J Colorectal Dis; 2010 Mar; 25(3):303-11. PubMed ID: 20012301
[TBL] [Abstract][Full Text] [Related]
2. Specific protein 1(SP1) regulates the epithelial-mesenchymal transition via lysyl oxidase-like 2(LOXL2) in pancreatic ductal adenocarcinoma.
Kim IK; Lee YS; Kim HS; Dong SM; Park JS; Yoon DS
Sci Rep; 2019 Apr; 9(1):5933. PubMed ID: 30976063
[TBL] [Abstract][Full Text] [Related]
3. Emerging role of LOXL2 in the promotion of pancreas cancer metastasis.
Park JS; Lee JH; Lee YS; Kim JK; Dong SM; Yoon DS
Oncotarget; 2016 Jul; 7(27):42539-42552. PubMed ID: 27285767
[TBL] [Abstract][Full Text] [Related]
4. Clinical Implications of Lysyl Oxidase-Like Protein 2 Expression in Pancreatic Cancer.
Tanaka N; Yamada S; Sonohara F; Suenaga M; Hayashi M; Takami H; Niwa Y; Hattori N; Iwata N; Kanda M; Tanaka C; Kobayashi D; Nakayama G; Koike M; Fujiwara M; Fujii T; Kodera Y
Sci Rep; 2018 Jun; 8(1):9846. PubMed ID: 29959362
[TBL] [Abstract][Full Text] [Related]
5. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer.
Arumugam T; Ramachandran V; Fournier KF; Wang H; Marquis L; Abbruzzese JL; Gallick GE; Logsdon CD; McConkey DJ; Choi W
Cancer Res; 2009 Jul; 69(14):5820-8. PubMed ID: 19584296
[TBL] [Abstract][Full Text] [Related]
6. The role of LOXL2 induced by glucose metabolism-activated NF-κB in maintaining drug resistance through EMT and cancer stemness in gemcitabine-resistant PDAC.
Lee YS; Kim HS; Kim HJ; Kang HW; Lee DE; Kim MJ; Hong WC; Kim JH; Kim M; Cheong JH; Park JS
J Mol Med (Berl); 2023 Nov; 101(11):1449-1464. PubMed ID: 37737908
[TBL] [Abstract][Full Text] [Related]
7. TM4SF1 Promotes Gemcitabine Resistance of Pancreatic Cancer In Vitro and In Vivo.
Cao J; Yang J; Ramachandran V; Arumugam T; Deng D; Li Z; Xu L; Logsdon CD
PLoS One; 2015; 10(12):e0144969. PubMed ID: 26709920
[TBL] [Abstract][Full Text] [Related]
8. Lysyl oxidase-like 2 as a new poor prognosis marker of squamous cell carcinomas.
Peinado H; Moreno-Bueno G; Hardisson D; Pérez-Gómez E; Santos V; Mendiola M; de Diego JI; Nistal M; Quintanilla M; Portillo F; Cano A
Cancer Res; 2008 Jun; 68(12):4541-50. PubMed ID: 18559498
[TBL] [Abstract][Full Text] [Related]
9. Lysyl oxidase family activity promotes resistance of pancreatic ductal adenocarcinoma to chemotherapy by limiting the intratumoral anticancer drug distribution.
Le Calvé B; Griveau A; Vindrieux D; Maréchal R; Wiel C; Svrcek M; Gout J; Azzi L; Payen L; Cros J; de la Fouchardière C; Dubus P; Guitton J; Bartholin L; Bachet JB; Bernard D
Oncotarget; 2016 May; 7(22):32100-12. PubMed ID: 27050073
[TBL] [Abstract][Full Text] [Related]
10. ZIP4 Increases Expression of Transcription Factor ZEB1 to Promote Integrin α3β1 Signaling and Inhibit Expression of the Gemcitabine Transporter ENT1 in Pancreatic Cancer Cells.
Liu M; Zhang Y; Yang J; Cui X; Zhou Z; Zhan H; Ding K; Tian X; Yang Z; Fung KA; Edil BH; Postier RG; Bronze MS; Fernandez-Zapico ME; Stemmler MP; Brabletz T; Li YP; Houchen CW; Li M
Gastroenterology; 2020 Feb; 158(3):679-692.e1. PubMed ID: 31711924
[TBL] [Abstract][Full Text] [Related]
11. Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205.
Chaudhary AK; Mondal G; Kumar V; Kattel K; Mahato RI
Cancer Lett; 2017 Aug; 402():1-8. PubMed ID: 28536008
[TBL] [Abstract][Full Text] [Related]
12. Silencing of lysyl oxidase‑like 2 inhibits the migration, invasion and epithelial‑to‑mesenchymal transition of renal cell carcinoma cells through the Src/FAK signaling pathway.
Hong X; Yu JJ
Int J Oncol; 2019 May; 54(5):1676-1690. PubMed ID: 30816490
[TBL] [Abstract][Full Text] [Related]
13. Inactivation of ATF-2 enhances epithelial-mesenchymal transition and gemcitabine sensitivity in human pancreatic cancer cells.
Wu X; Liu Z; Guo K; Ma G; Song S
J Cell Biochem; 2019 Mar; 120(3):4463-4471. PubMed ID: 30367508
[TBL] [Abstract][Full Text] [Related]
14. Neural Wiskott-Aldrich syndrome protein (N-WASP) promotes distant metastasis in pancreatic ductal adenocarcinoma via activation of LOXL2.
Kim HS; Lee YS; Dong SM; Kim HJ; Lee DE; Kang HW; Kim MJ; Park JS
Oncol Res; 2024; 32(4):615-624. PubMed ID: 38560567
[TBL] [Abstract][Full Text] [Related]
15. Sclareolide enhances gemcitabine‑induced cell death through mediating the NICD and Gli1 pathways in gemcitabine‑resistant human pancreatic cancer.
Chen S; Wang Y; Zhang WL; Dong MS; Zhang JH
Mol Med Rep; 2017 Apr; 15(4):1461-1470. PubMed ID: 28259943
[TBL] [Abstract][Full Text] [Related]
16. The long non-coding RNA HOTTIP promotes progression and gemcitabine resistance by regulating HOXA13 in pancreatic cancer.
Li Z; Zhao X; Zhou Y; Liu Y; Zhou Q; Ye H; Wang Y; Zeng J; Song Y; Gao W; Zheng S; Zhuang B; Chen H; Li W; Li H; Li H; Fu Z; Chen R
J Transl Med; 2015 Mar; 13():84. PubMed ID: 25889214
[TBL] [Abstract][Full Text] [Related]
17. Interdependence of gemcitabine treatment, transporter expression, and resistance in human pancreatic carcinoma cells.
Hagmann W; Jesnowski R; Löhr JM
Neoplasia; 2010 Sep; 12(9):740-7. PubMed ID: 20824050
[TBL] [Abstract][Full Text] [Related]
18. Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells.
Li Y; VandenBoom TG; Kong D; Wang Z; Ali S; Philip PA; Sarkar FH
Cancer Res; 2009 Aug; 69(16):6704-12. PubMed ID: 19654291
[TBL] [Abstract][Full Text] [Related]
19. Silencing pancreatic adenocarcinoma upregulated factor (PAUF) increases the sensitivity of pancreatic cancer cells to gemcitabine.
Gao CC; Xu XL; Li F; Gong BG; Liu S; Cui YQ; Sun HC; Xu PY; Zheng YM; Jiang H
Tumour Biol; 2016 Jun; 37(6):7555-64. PubMed ID: 26684804
[TBL] [Abstract][Full Text] [Related]
20. Hydroxyurea decreases gemcitabine resistance in pancreatic carcinoma cells with highly expressed ribonucleotide reductase.
Funamizu N; Kamata Y; Misawa T; Uwagawa T; Lacy CR; Yanaga K; Manome Y
Pancreas; 2012 Jan; 41(1):107-13. PubMed ID: 21926937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
